Macrolide Resistance in Bacteremic Pneumococcal Disease: Implications for Patient Management

N. Daneman, A. McGeer, K. Green, and D. E. Low, for the Toronto Invasive Bacterial Diseases Network*

Department of Laboratory Medicine and Pathobiology, University of Toronto, and Shared Department of Microbiology, Mount Sinai Hospital and University Health Network, Toronto, Ontario, Canada


Methods. Prospective, population-based surveillance was conducted to identify cases of pneumococcal bacteremia in Toronto and Peel, Canada, between 2000 and 2004. "Macrolide failures" were defined as cases of bacteremia occurring during outpatient treatment with macrolide antibiotics or within 2 days after treatment. Macrolide susceptibility was determined according to Clinical Laboratory Standards Institute guidelines; common macrolide resistance mechanisms were determined by genotyping.

Results. During the 5 years of surveillance, there were 1696 episodes of pneumococcal bacteremia (8.5 cases/100,000 population/year), of which 60 (3.5%) were failures of outpatient macrolide therapy. Resistant isolates were more common among cases of bacteremia after failure of macrolide therapy (37 [64%] of 58 cases) than among cases of bacteremia after failure of nonmacrolide antibiotics (16 [22%] of 74 cases; P < .001) or cases of bacteremia that occurred without prior antibiotic therapy (193 [12%] of 1569 cases; P < .001). Macrolide failures were significantly more common among cases of pneumococcal bacteremia with isolates exhibiting an erythromycin MIC of 1 µg/mL than among isolates exhibiting MICs ≤0.25 µg/mL (3 [38%] of 8 cases vs. 21 [1.5%] of 1394 cases of bacteremia; P < .001). Increases in the MIC to 1 µg/mL were not associated with further increases in the likelihood of macrolide failure. Low-level resistance conferred by mefA and high-level resistance conferred by ermB were equally overrepresented among macrolide failures.

Conclusions. Macrolide resistance contributes to an increased risk of macrolide failure, irrespective of the underlying resistance mechanism or of the degree of elevation in erythromycin MIC.

Streptococcus pneumoniae is the most commonly identified cause of serious bacterial illness in young children and of community-acquired pneumonia (CAP) in adults. Macrolide antibiotics are currently the second most commonly prescribed class of antibiotics in the United States [1] and are often recommended as empirical therapy for patients with suspected pneumococcal infections, including CAP, despite reported rates of pneumococcal macrolide resistance in excess of 29% [2–4]. Macrolide resistance in S. pneumoniae occurs via 2 major mechanisms: methylation of ribosomal macrolide target sites, encoded by the ermB gene, and drug efflux, encoded by mefA [3]. Pneumococcal macrolide resistance in the United States is predominantly mediated by drug efflux (70%) [4]. Efflux-mediated resistance is a low-level resistance (erythromycin MIC usually 0.5–8 µg/mL), whereas ribosomal methylation is associated with high-level resistance (MIC, ≥16 µg/mL) [3].

In the past 2 decades, there have been an increasing number of reports of macrolide treatment failure for pneumococcal infections with macrolide-resistant isolates [5]. Although it is not surprising that highly resistant strains (MIC, ≥16 µg/mL) may lead to clinical failure, the relevance of low-level resistance (MIC, 0.5–8 µg/mL) has been brought into question. Clinical reports of macrolide-resistant pneumococcal failures and evidence from animal models suggest that infections caused by isolates with MICs ≤8 µg/mL may respond to clarithromycin [5]. We sought to use pro-
spective, population-based surveillance to determine whether macrolide resistance is a cause of failure of macrolide therapy for serious pneumococcal disease.

METHODS

Population-based surveillance. The Toronto Invasive Bacterial Disease Network (TIBDN) has conducted prospective, population-based surveillance of invasive pneumococcal disease in metropolitan Toronto and the adjacent regional municipality of Peel, in Ontario, Canada (population, 4 million), since 1 January 1995. The surveillance network includes all hospital-based laboratories in hospitals to which residents of the population area may be admitted, as well as the 2 largest of the 3 population-based surveillance of invasive pneumococcal disease in the central study laboratory and the National Streplococcal Centre in Edmonton, Alberta, according to standard methodology [11]. The mefA and ermB genes are detected by PCR, as described by Katz et al. [12].

Statistical analysis. All clinical and laboratory data were stored, sorted, and analyzed using SAS statistical software, version 9.1 (SAS Institute). Differences in group proportions were assessed by Fisher’s exact test (2-tailed), and differences in medians were assessed by the Wilcoxon rank sum test. The primary outcome was the difference in the proportion of macrolide-resistant isolates in episodes of macrolide treatment failure compared to other episodes of pneumococcal bacteremia. Secondary analyses included reanalysis using different MIC breakpoints, comparisons of the prevalence of mefA and ermB genes, exclusion of patients with meningitis, and inclusion, as failures, of those patients still receiving macrolides at the time their blood culture was performed. Multivariable logistic-regression models were used to assess risk factors for macrolide failure. Variables included in the models were those potentially associated with these outcomes in univariate analysis (P < .15), after assessment for colinearity.

RESULTS

Clinical characteristics of patients for whom macrolide therapy failed. During the 5-year period of active surveillance, 1696 episodes of pneumococcal bacteremia were detected, corresponding to a rate of 8.5 cases per 100,000 population-year. Of these cases, 60 (3.5%) represented failures of outpatient macrolide therapy, including 32 clarithromycin failures, 22 azithromycin failures, 3 erythromycin failures, 2 failures of combined azithromycin and clarithromycin, and 1 failure of clarithromycin and erythromycin. All patients were taking oral therapy. Detailed data permitting the assessment of appropriateness of dosing was not requested in the surveillance system, but diagnosis and dose of macrolides were frequently provided. Of the 28 persons for whom dosing information permitting assessment of appropriateness was available, 27 (96%) had received recommended doses. Six of the 60 patients for whom macrolide therapy failed had also been treated with another antibiotic (2 had received amoxicillin, and 1 each had received sulfamethoxazole, cefaclor, penicillin, and combined sulfamethoxazole and amoxicillin). The clinical diagnoses were: pneumonia (36 [60%] of 60), primary bacteremia (8 [13%]), meningitis (7 [12%]), otitis media (5 [8%]), pneumonia and meningitis (3 [5%]), and osteomyelitis (1 [2%]). Almost all
patients (56 [93%] of 60) were admitted to the hospital, and 9 (15%) of 60 died.

Pneumococcal isolates were available for 58 of the 60 episodes of bacteremia associated with macrolide failure: 21 (36%) were macrolide susceptible, and 37 (64%) were macrolide resistant. Sixteen different serotypes were associated with macrolide failures: the most common were 14 (17 cases), 6B (14 cases), 6A (5 cases), and 19F (4 cases). Compared with failures associated with macrolide-resistant isolates, failures associated with macrolide-susceptible isolates were more likely to occur in patients who were ≥65 years of age (10 [48%] of 21 vs. 5 [14%] of 37; P = .01), who had underlying cardiac disease (7 [33%] of 21 vs. 3 [8%] of 37; P = .03), and who were residents of nursing or retirement homes (7 [33%] of 21 vs. 2 [5%] of 37; P = .008).

The median time from initiation of macrolide therapy to the development of a positive blood culture result was 3 days (range, 0–17 days). Five (33%) of 15 isolates obtained from patients presenting with bacteremia <48 h after initiating macrolide therapy were macrolide resistant, compared with 31 (74%) of 42 isolates from patients who experienced treatment failure >2 days after initiation of therapy (figure 1) (P = .01). The timing of macrolide failure and the likelihood of obtaining a resistant isolate were similar for cases of pneumonia and nonrespiratory foci of infection (data not shown). Twenty-nine (66%) of 44 patients who were still taking a macrolide at presentation to the hospital with bacteremia had a macrolide-resistant isolate, compared with 8 (57%) of 14 who had completed or discontinued macrolide therapy in the 48 h before presentation (P = .78).

**Comparison of cases of macrolide failure with other cases of pneumococcal bacteremia.** Macrolide-resistant isolates were much more common among the cases of macrolide failure than among other cases of pneumococcal bacteremia (37 [64%] of 58 cases vs. 193 [12%] of 1569 cases; P < .001) (figure 2). Macrolide-resistant isolates were also more common among patients for whom macrolide therapy failed than among those for whom nonmacrolide antibiotic therapy failed (37 [64%] of 58 cases vs. 16 [22%] of 74 cases; P < .001) (figure 2).

In univariate analysis, patients for whom macrolide therapy failed were more likely than other patients to be children (age, <15 years), to have no chronic underlying illness, and to have received a macrolide antibiotic for another reason during the previous 3 months (table 1). However, there was no difference in the 30-day mortality rate (9 [15%] of 60 cases of macrolide failure vs. 291 [18%] of 1594 other cases; P = .96). In multivariate logistic regression, erythromycin resistance in the infecting isolate (OR, 12.3; 95% CI, 7.0–22; P < .001), age (OR per decade, 1.15; 95% CI 1.04–1.27; P = .005), and residence...
Mechanisms of macrolide resistance. Among the 32 macrolide-resistant isolates recovered from patients who experienced macrolide failure available for PCR analysis, 17 (53%) were positive for mefA, 14 (44%) were positive for ermB, and 1 (3%) was positive for both mefA and ermB (figure 3).

The efflux gene mefA was overrepresented among macrolide failure cases than among cases of pneumococcal bacteremia that were not associated with failure of macrolide therapy (34% vs. 6.6% were PCR positive for mefA; P < .001). Similarly, ribosomal modification (ermB) was overrepresented among macrolide failure cases (32% vs. 5.1% were PCR positive for ermB; P < .001). The distribution of ermB and mefA genotypes in erythromycin-resistant isolates from cases for which macrolide failure occurred (17 ermB:14 mefA:1 both) was not different from the distribution of these genotypes in other cases (94 ermB:70 mefA:10 both; P = .80).

Low-level versus high-level macrolide resistance. Of macrolide-resistant isolates from cases of macrolide failure, 17 (46%) of 37 had low-level resistance (erythromycin MIC, 1–8 μg/mL), compared with 83 (43%) of 193 macrolide-resistant isolates not associated with failure of macrolide therapy (P = .74).

Macrolide failures were significantly more common among patients with pneumococcal bacteremia with isolates exhibiting an erythromycin MIC of 1 μg/mL compared with isolates exhibiting MICs ≤0.25 μg/mL (3 [38%] 8 vs. 21 [1.5%] of 1394 cases of bacteremia; P < .001). Increases in the MIC >1 μg/mL were not associated with further increases in the likelihood of macrolide failure (figure 4).

Isolates with low-level resistance contributed to 4 (29%) of 14 failures of azithromycin alone and 10 (56%) of 18 failures of clarithromycin alone (P = .24). The median erythromycin MIC was not different among isolates from patients who experienced clarithromycin failure and those from patients who experienced azithromycin failure (2 μg/mL vs. 8 μg/mL; P = .19).

Secondary analyses. All analyses described above were also

Table 1. Comparison of clinical characteristics and of outcomes for patients with pneumococcal bacteremia for whom macrolide therapy failed or did not fail, Toronto Invasive Bacterial Diseases Network, 2000–2004.

<table>
<thead>
<tr>
<th>Clinical characteristic</th>
<th>Macrolide failure with pneumococcal bacteremia</th>
<th>Other cases of pneumococcal bacteremia</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &lt;15 years</td>
<td>27/60 (45)</td>
<td>400/1636 (24)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Female sex</td>
<td>25/60 (42)</td>
<td>724/1636 (44)</td>
<td>.79</td>
</tr>
<tr>
<td>Chronic underlying illness</td>
<td>23/59 (39)</td>
<td>928/1599 (58)</td>
<td>.006</td>
</tr>
<tr>
<td>Macrolide use in prior 3 monthsa</td>
<td>5/60 (8.3)</td>
<td>57/1636 (3.5)</td>
<td>.06</td>
</tr>
<tr>
<td>Year of infection</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2000</td>
<td>9 (15)</td>
<td>356 (22)</td>
<td>.21</td>
</tr>
<tr>
<td>2001</td>
<td>19 (32)</td>
<td>320 (20)</td>
<td></td>
</tr>
<tr>
<td>2002</td>
<td>10 (17)</td>
<td>321 (20)</td>
<td></td>
</tr>
<tr>
<td>2003</td>
<td>9 (15)</td>
<td>282 (17)</td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td>13 (22)</td>
<td>357 (22)</td>
<td></td>
</tr>
<tr>
<td>ICU admission</td>
<td>7/60 (12)</td>
<td>352/1572 (22)</td>
<td>.07</td>
</tr>
<tr>
<td>30-day mortality</td>
<td>9/60 (15)</td>
<td>229/1594 (18)</td>
<td>.96</td>
</tr>
</tbody>
</table>

NOTE. Data are no. (%) of patients or no. of patients with finding/no. studied (%). ICU, intensive care unit.
a Received a macrolide antibiotic for a reason other than treatment of this episode of infection at some time in the 3 months before this infection.
DISCUSSION

Although pneumococcal resistance rates to macrolide antimicrobial agents exceed 25% in many parts of the world, these agents are still recommended as empirical therapy for CAP in most guidelines [13]. Previous studies may have failed to detect true macrolide treatment failures as a result of methodologic limitations, such as a reliance on rare failure end points like mortality, or by not focusing on cases of discordant therapy [14]. The current study sought to overcome these methodologic challenges by first identifying macrolide failures that resulted in pneumococcal bacteremia and then evaluating the relative proportion of macrolide-resistant isolates among these failures.

Our results establish that macrolide resistance among pneumococci is a cause of failure of outpatient pneumonia therapy. Clinicians should be aware that macrolide resistance precludes the use of macrolide therapy for pneumococcal pneumonia. Unfortunately, pathogens are isolated in fewer than one-half of CAP episodes [15, 16]. Even when a pathogen is isolated, a critical period of time elapses, during which the treating physician must select appropriate antimicrobials although identification and susceptibility testing results are not available [17].

Therefore, it would be wise to avoid empirical macrolide therapy when a patient is at risk of being infected with a macrolide-resistant pathogen, either as a result of patient-specific characteristics or the overall rate of resistance in the community. Treatment guidelines recommend avoiding macrolide use in patients with macrolide exposure within the previous 3 months [18, 19]. Other clinical parameters associated with macrolide resistance among pneumococci include recent use of a penicillin or trimethoprim-sulfamethoxazole [6, 20], extremes of age [20], HIV infection [6], and exposure to siblings colonized with resistant isolates [21].

Our results indicate that methylation of the ribosomal target site, conferred by the ermB gene, and efflux, conferred by the mefA gene, are equally overrepresented among cases of pneumococcal bacteremia that occur after macrolide failure. Furthermore, azithromycin and clarithromycin failures were associated with both low-level and high-level resistance. Therefore, macrolide resistance contributes to an increased risk of macrolide failure independent of the underlying resistance mechanism, the degree of elevation in erythromycin MIC, or the macrolide being used for therapy. This contradicts the arguments of some authorities, who believe that the ability of macrolide antibiotics to concentrate within the epithelial lining fluid of the lung might allow drugs to overcome low-level MICs associated with the presence of the mefA genotype [22].

A proportion of patients might be expected to experience outpatient oral antimicrobial therapy failure despite the presence of a drug-susceptible isolate, on the basis of noncompliance with therapy, impaired absorption, an overwhelming bacterial burden, or multiorgan failure resulting from the systemic inflammatory response syndrome [23]. In this study, patients with susceptible isolates for whom therapy failed were older, more likely to have underlying cardiac disease, more likely to live in nursing homes, and more likely to be admitted to the hospital within the first 48 h of therapy. This suggests that, in addition to discordant therapy, inadequate host response is an important reason for treatment failure. The apparent contradiction between our results and those of an earlier case-control study of macrolide failures resulting in pneumococcal bacteremia, which detected no macrolide failures with macrolide-susceptible isolates, is explained by study design. Macrolide failures constituted only 1.4% of infections with macrolide-susceptible isolates in our cohort, a proportion low enough that failures might not be detected with a sample size of 136 control subjects [24].

Our data reveal that macrolide resistance is overrepresented, even among early macrolide failures. This is consistent with recent pneumonia studies that have documented that the median time to defervescence and normalization of respiratory rate is 1 day and that the median time to stabilization of chest radiography and normalization of oxygenation is 2 days [25]. Therefore, if a patient is admitted to the hospital with worsening pneumonia while receiving macrolide therapy, it would...
be prudent to switch to a different class of agents, even if macrolide therapy was initiated within the preceding 24–48 h.

One of the greatest strengths of our surveillance approach is its sensitivity to detect cases of macrolide failure by evaluating cases of pneumococcal bacteraemia. Indeed, the number of cases detected during our investigation ($n = 60$) is nearly double the number of cases reported in the literature to date. However, a limitation of this approach is that the rate of macrolide failure cannot be evaluated, because cases of successful macrolide therapy are not identified and cannot be counted. The goal of this study was not to determine the rate of failure of macrolide therapy, but to identify whether in vitro macrolide resistance is associated with failure of macrolide therapy. Another limitation of this study is that the power to detect differences in subgroups is low. For instance, although we did not detect differences in the rates of resistance to erythromycin in infecting isolates in patients failing different macrolide antibiotics, it is not possible to conclude that such differences do not exist.

Our study demonstrates that macrolide resistance is an important cause of macrolide therapy failure. Therefore, macrolide antibiotic use should be avoided for patients with known clinical risk factors for macrolide resistance and for patients residing in areas with high rates of macrolide resistance. Patients admitted to the emergency department with CAP who are deteriorating despite receiving macrolide therapy should receive therapy with a different class of antibiotics.

**THE TORONTO INVASIVE BACTERIAL DISEASES NETWORK**

Collaborating investigators in the Toronto Invasive Bacterial Disease Network are as follows: P. Da Camara and J. Downey, Toronto East General Hospital (Toronto, Ontario, Canada); H. R. Devlin, St. Michael’s Hospital (Toronto); H. Dick, Vita-Tech Laboratories (Toronto); I. N. Gaid and I. Kitai, Rouge Valley Health System (Toronto); P. Garrod and N. Rau, Halton Healthcare Services (Oakville, Ontario, Canada); R. Lovinsky, D. Noria, D. Rose, and J. Braithwaite, The Scarborough Hospital (Toronto); F. Jamieson, Ontario Public Health Laboratory (Toronto); R. Grossman, Credit Valley Hospital (Mississauga, Ontario, Canada); J. Kapala, Gamma Dynacare Laboratories (Toronto); S. Krajden, St. Joseph’s Health Centre (Toronto); K. S. Lee and M. Baqi, Humhub River Regional Hospital (Toronto); M. Loeb and F. Smaill, Hamilton Health Sciences Centre (Hamilton, Ontario, Canada); M. Lovgren and G. Tyrell, National Centre for Streptococcus (Edmonton, Alberta, Canada); A. G. Matlow, Hospital for Sick Children (Toronto); R. McKeown, Peel Region Health Department (Brampton, Ontario, Canada); B. Mederski and K. Katz, North York General Hospital (North York, Ontario, Canada); Z. Moloo, D. Richardson, and C. Quan, William Osler Health Care Centre (Brampton); M. Naas, British Columbia Centers for Disease Control (Vancouver, British Columbia, Canada); K. Ostrowska and A. Sarabia, Trillium Health Centre (Mississauga); P. Shokry and I. Ephthimiou, Markham Stouffville Hospital (Markham, Ontario, Canada); A. E. Simor and M. Vearncombe, Sunnybrook and Women’s College Health Science Centre (Toronto); D. Sturman, Bridgepoint Hospital (Toronto); P. Van Nostrand, The Rehabilitation Institute of Toronto (Toronto); S. Walmsley, University Health Network (Toronto); B. Willey, S. Pong-Porter, and A. Plevesnesi, Toronto Medical Labs/Mount Sinai Hospital (Toronto); B. Yaffe, City of Toronto Public Health (Toronto); D. Yamamura, MDS Laboratories (Toronto); M. Silverman, LakeRidge Health (Oshawa, Ontario, Canada); R. Robertson, Royal Victoria Hospital (Barrie, Ontario, Canada); and G. Volkening, Southlake Regional Health Center (Newmarket, Ontario, Canada).

**Acknowledgments**

We are grateful to the infection-control practitioners, microbiology laboratory technologists, and public health staff of the Toronto Invasive Bacterial Disease Network, for their ongoing contribution to surveillance, and we thank the many patients and physicians who have willingly agreed to participate in this study. We also thank Sylvia Pong-Porter and Yana Rzayev for their tireless efforts in performing identification and susceptibility testing for all isolates, Carla Duncan for performing PCR analysis, Shaparak Malek for serotyping of isolates, and Raymond Chow for design of graphs. We are especially grateful to the enthusiastic and committed research staff of TIBDN, without whose efforts this work would not be possible: Agron Plevesnesi, Nilofar Siddiqi, Lynda Eunson, Nada Cicovic-Gebert, Sharon Miller, Lisa Landry, Ellie Goldenberg, Albynay Shigayaeva, and Charlotte Ma.

**Financial support.** Canadian Institutes for Health Research, Ontario Thoracic Society, Abbott Laboratories of Canada, Sanofi-aventis and Bayer Healthcare.

**Potential conflicts of interest.** D.E.L. and A.M. have received grant support from Bayer Healthcare, Hoffman LaRoche, Abbott Laboratories, Pfizer, Bristol-Myers Squibb, and Sanofi-aventis. All other authors: no conflicts.

**References**

8. NCCLS. Methods for dilution antimicrobial susceptibility tests for bac-


